Sort
10,766 grants matching “checkpoint inhibitor”
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
$700,561Catherine Sibyl Diefenbach · New York University School Of Medicine · R01 · FY2025 · CA
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
$700,539Kamal V. Kannan · Metaclipse Therapeutics Corporation · R44 · FY2017 · CA
The Epigenetic Enzyme CARM1 as a Negative Regulator of Dendritic cells and CD8 T cells in Melanoma
$700,514Kai W Wucherpfennig · Massachusetts General Hospital · P01 · FY2024 · CA
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
$700,162William R. Drobyski · Medical College Of Wisconsin · R01 · FY2022 · HL
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
$700,162William R. Drobyski · Medical College Of Wisconsin · R01 · FY2023 · HL
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
$700,162William R. Drobyski · Medical College Of Wisconsin · R01 · FY2021 · HL
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$700,147Diane M Simeone · New York University School Of Medicine · R01 · FY2020 · CA
Small extracellular vesicles as biomarkers of prognosis and response to therapy in head and neck cancer
$700,037Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DE
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches
$699,639Cheryl A London · Tufts University Boston · U01 · FY2020 · CA
Understanding IDH mutant gliomas
$699,386Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Depleting exosomes to improve responses to immune therapy in HNSCC
$699,220Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2024 · DE
Population Modeling of Bladder Cancer Detection and Control
$699,128Thomas Trikalinos · Brown University · U01 · FY2025 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$699,062Elad Ziv · University Of California, San Francisco · R01 · FY2018 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$698,751Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Regulation of Mucosal Lymphocytes
$698,556Richard S Blumberg · Brigham And Women'S Hospital · R01 · FY2017 · DK
Radiation-induced translational control of gene expression
$697,852Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Evolution of gliomas during treatment and resistance
$697,603Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$697,232Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$697,166Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$696,801Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2025 · CA
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$696,769Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Enhancing the efficacy of immunotherapy in DLBCL using rational combination approaches
$696,529Cheryl A London · Tufts University Boston · U01 · FY2021 · CA
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
$695,955Michael Karin · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers
$695,916Robert H Blelloch · University Of California, San Francisco · R01 · FY2024 · CA
Immunogen design and testing
$695,598Barton F Haynes · University Of Pennsylvania · P01 · FY2018 · AI